Bacil Pharma Ltd

Bacil Pharma has shown zero net sales and operating income from March 2019 to March 2025, but achieved a turnaround in March 2025 with a positive operating profit of 0.41 crore and profit after tax of 0.40 crore. Total assets increased significantly to 25.55 crore, indicating a potential recovery after years of financial challenges.

As of May 26, 2025, Bacil Pharma shows a mildly bullish trend due to daily moving averages and monthly MACD signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution.

As of November 17, 2023, Bacil Pharma is considered risky and overvalued with a PE ratio of 24.47 and a troubling ROCE of -13.29%, despite a strong one-year stock return of 70.54%, contrasting with a year-to-date decline of 27.35%.